Cite
HARVARD Citation
Janjigian, Y. et al. (2020). First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet oncology. 21 (6), pp. 821-831. [Online].